Description
Similarity: Contains 3 cystatin domains.
Function: (1) Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.
Function: (1) Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.
Additional Information
| Name | SYNTHETIC Human KALLIDIN II Protein (GWB-18A216) |
|---|---|
| Related Product Names | SYNTHETIC HUMAN KALLIDIN II BDK; KNGKALLIDIN IIKNG1 |
| Description of Target | SYNTHETIC HUMAN KALLIDIN II |
| Gene Symbol | KNG1 |
| Gene Family | ENDOLIG |
| Gene id | 3827 |
| Alias Symbols | BDK, KNG, KNG1 |
| Swissprot ID | P01042 |
| Protein Name | Kininogen-1 |
| Protein Accession Num | NP_000884.1 |
| Peptide Sequence | KRPPGFSPFR |
| Homology | Human |
| Product Format | Purified synthetic peptide - lyophilised |
| Molecular Weight | 1188.2 Da_x000D_ |
| Purity | HPLC: >99%_x000D_ |
| Application | ELISA |
| Format | Purified |
| Stability | 18 months from date of despatch. |
| Reconstitution and Storage | Reconstitution: Reconstitute with 1.0ml distilled water Care should be taken during reconstitution as the protein may appear as a film at the bottom of the vial. Aviva Systems Biology recommend that the vial is gently mixed after reconstitution. |
| Reactivity | Human |
| Storage | Prior to reconstitution store at +4 degree C. After reconstitution store at -20 degree C. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the prot |
| Datasheets/Manuals | Printable datasheet for GWB-18A216 |
| Species Reactivity | Human |
| Lead Time | Domestic: within 2-3 weeks delivery | International: 2-3 weeks |
| Intended Use | Research Use Only |
| Additional Information | Approx Protein Conc: 5.0 mg/ml Buffer solution: Acetate salt |
| :: | Label Protein Molar Ratio: Solid phase synthesis Preservative: None present |